Charles H Mitch
Overview
Explore the profile of Charles H Mitch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chappell M, Li R, Smith S, Dressman B, Tromiczak E, Tripp A, et al.
J Med Chem
. 2016 Dec;
59(24):10974-10993.
PMID: 28002967
As part of our ongoing efforts to identify novel ligands for the metabotropic glutamate 2 and 3 (mGlu) receptors, we have incorporated substitution at the C3 and C4 positions of...
2.
Dressman B, Tromiczak E, Chappell M, Tripp A, Quimby S, Vetman T, et al.
Bioorg Med Chem Lett
. 2016 Nov;
26(23):5663-5668.
PMID: 27836401
Negative modulators of metabotropic glutamate 2 & 3 receptors demonstrate antidepressant-like activity in animal models and hold promise as novel therapeutic agents for the treatment of major depressive disorder. Herein...
3.
Witkin J, Ornstein P, Mitch C, Li R, Smith S, Heinz B, et al.
Neuropharmacology
. 2016 Jan;
115:100-114.
PMID: 26748052
Metabotropic glutamate (mGlu) receptors are of considerable interest owing to their role in modulating glutamate transmission via presynaptic, postsynaptic and glial mechanisms. As part of our ongoing efforts to identify...
4.
Rorick-Kehn L, Witcher J, Lowe S, Gonzales C, Weller M, Bell R, et al.
Int J Neuropsychopharmacol
. 2015 Feb;
18(2).
PMID: 25637376
Background: Selective kappa opioid receptor antagonism is a promising experimental strategy for the treatment of depression. The kappa opioid receptor antagonist, LY2456302, exhibits ~30-fold higher affinity for kappa opioid receptors...
5.
Wang C, Eessalu T, Barth V, Mitch C, Wagner F, Hong Y, et al.
Am J Nucl Med Mol Imaging
. 2014 Jan;
4(1):29-38.
PMID: 24380043
Hydroxamic acid-based histone deacetylase inhibitors (HDACis) are a class of molecules with therapeutic potential currently reflected in the use of suberoylanilide hydroxamic acid (SAHA; Vorinostat) to treat cutaneous T-cell lymphomas...
6.
Rorick-Kehn L, Witkin J, Statnick M, Eberle E, McKinzie J, Kahl S, et al.
Neuropharmacology
. 2013 Sep;
77:131-44.
PMID: 24071566
Kappa opioid receptors and their endogenous neuropeptide ligand, dynorphin A, are densely localized in limbic and cortical areas comprising the brain reward system, and appear to play a key role...
7.
Mitch C, Quimby S, Diaz N, Pedregal C, de la Torre M, Jimenez A, et al.
J Med Chem
. 2011 Oct;
54(23):8000-12.
PMID: 21958337
Arylphenylpyrrolidinylmethylphenoxybenzamides were found to have high affinity and selectivity for κ opioid receptors. On the basis of receptor binding assays in Chinese hamster ovary (CHO) cells expressing cloned human opioid...
8.
Melief E, Miyatake M, Carroll F, Beguin C, Carlezon Jr W, Cohen B, et al.
Mol Pharmacol
. 2011 Aug;
80(5):920-9.
PMID: 21832171
The κ-opioid receptor is a widely expressed G-protein-coupled receptor that has been implicated in biological responses to pain, stress, anxiety, and depression, and its potential as a therapeutic target in...
9.
Sahr A, Sindelar D, Alexander-Chacko J, Eastwood B, Mitch C, Statnick M
Am J Physiol Regul Integr Comp Physiol
. 2008 Jun;
295(2):R463-71.
PMID: 18525013
An analog of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine series (LY255582) exhibits high in vitro binding affinity and antagonist potency for the mu-, delta-, and kappa-opioid receptors. In vivo, LY255582 exhibits potent effects in...
10.
Takeuchi K, Holloway W, Mitch C, Quimby S, McKinzie J, Suter T, et al.
Bioorg Med Chem Lett
. 2007 Nov;
17(24):6841-6.
PMID: 17980586
A series of 6-bicycloaryloxynicotinamides were identified as opioid receptor antagonists at mu, kappa, and delta receptors. Compounds in the 6-(2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yloxy)nicotinamide scaffold exhibited potent in vitro functional antagonism at all three...